Roquefort Therapeutics plc
ROQ.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | -£0 | -£0 | -£0 |
| % Margin | – | – | -592.2% | – |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £1 | £1 |
| SG&A Expenses | £0 | £0 | £1 | £1 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£1 | £0 | £0 |
| Operating Expenses | £0 | -£1 | £1 | £1 |
| Operating Income | -£0 | -£0 | -£1 | £1 |
| % Margin | – | – | -25,099.6% | – |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£2 |
| Pre-Tax Income | -£1 | -£1 | -£1 | -£1 |
| Tax Expense | £0 | £0 | £0 | -£0 |
| Net Income | -£0 | -£0 | -£1 | -£1 |
| % Margin | – | – | -21,447.1% | – |
| EPS | -0.003 | -0.003 | -0.005 | -0.007 |
| % Growth | -10% | 33.3% | 36.6% | – |
| EPS Diluted | -0.003 | -0.003 | -0.005 | -0.007 |
| Weighted Avg Shares Out | 148 | 130 | 129 | 136 |
| Weighted Avg Shares Out Dil | 148 | 131 | 129 | 136 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£1 | -£1 |
| % Margin | – | – | -24,999.6% | – |